The Australian Genomic Cancer Medicine Centre (AGCMC) and Molecular Screening and Therapeutics (MoST)

  • GROUP Rare Cancers
  • PROJECT SPAN 2022
  • DATE 02/05/2022

Overview

The AGCMC is a national network of eight cancers centres – one centre in every state and territory in Australia – that delivers the Australian Genomics Cancer Medicine Program.

Details on this project

The program oversees precision oncology clinical trials and screening studies including: the Molecular Screening and Therapeutics (MoST) study; Genic Cancer Risk in the Young (RisC) study; and Surveillance study in Multi-Organ prone syndromes (SMOC+).

The primary AGCMC centres are:

  • Canberra Hospital, ACT
  • The Kinghorn Cancer Centre/Garvan Institute, NSW
  • Peter MacCallum Cancer Centre, VIC
  • Prince Alexandra Hospital, QLD
  • Royal Adelaide Hospital, SA
  • Royal Darwin Hospital, NT
  • Royal Hobart Hospital, TAS
  • Sir Charles Gairdner Hospital, WA

The MoST study performs genomic profiling to analyse the molecular characteristics of a patient’s tumour, and where possible, match them to a MoST therapeutic study (clinical trial) or other targeted therapy. Suitable patients include those aged 16 years and older with an advanced and/or metastatic sold or blood cancer with limited treatment options, and who are fit enough and willing to participate in a clinical trial. The study is targeting rare and less common cancers.

For more information visit omico.com.au

Related projects

Related Project Image

Rare Cancers

The Australian Rare Cancer (ARC) Portal
Related Project Image

Rare Cancers

The Stafford Fox Rare Cancer Program (SFRCP)